Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT02978443 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT02978443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02978443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Terminated
Start date
July 26, 2017
Completion date
August 2, 2022
Enrollment
14 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acral lentiginous melanoma, mucosal melanoma